AnGes, Inc. (FRA:AJW)

Market Cap	134.28M +61.5%
Revenue (ttm)	4.75M +35.9%
Net Income	-27.83M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.2900
Previous Close	0.2780
Day's Range	0.2900 - 0.2900
52-Week Range	0.2360 - 0.6150
Beta	n/a
RSI	56.89
Earnings Date	Feb 10, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 55
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AJW

Financial Performance

In 2025, AnGes's revenue was 874.00 million, an increase of 35.93% compared to the previous year's 643.00 million. Losses were -5.12 billion, -81.79% less than in 2024.

Financial numbers in JPY